



# LLS Research Grants Program

*Supporting Blood Cancer Research Since 1949*

**We cover the full spectrum of blood cancer research**

from the earliest phase of discovery science to translational research that directly benefits our patients



Idea

Basic  
Research

Drug  
Discovery

Preclinical  
Research

Clinical  
Research

FDA  
Approval

New Idea Award (NIA)

Screen to Lead (SLP)

Translational Research Program (TRP)

Blood Cancer Discoveries Grant Program (BCDG)  
Discovery Grant Program (DGP)

Academic Clinical  
Trials Program (ACT)

Influential Medicine  
Providing Access To  
Clinical Trials (IMPACT)

Specialized Center of Research Program (SCOR)

Career Development Program (CDP)

**We create special initiatives to fund diseases with high unmet medical need:**

Mantle Cell Lymphoma  
(MCL2)

Chronic Myelomonocytic Leukemia  
(CMML Initiative)

Hairy cell leukemia  
(HCL2025)

Follicular lymphoma  
(RAFL)

Visit [www.LLS.org/Research](http://www.LLS.org/Research) for more information and funding opportunities



The mission of The Leukemia & Lymphoma Society (LLS) is to cure blood cancer and improve the quality of life of all patients and their families. Find out more at [www.LLS.org](http://www.LLS.org).

# EQUITY IN ACCESS PROGRAM GOALS

---

## ADVANCE UNDERSTANDING

of modifiable, underlying causes of inequitable access to care for blood cancer patients and survivors within the current healthcare system.

## GENERATE ACTIONABLE EVIDENCE

to assist LLS in advocating for policies and developing programs that tangibly improve the lives of blood cancer patients and survivors.

## IDENTIFY HEALTHCARE POLICIES AND PRACTICES

that have the potential to increase equitable access to cancer care and improve the quality of life and outcomes for blood cancer patients and survivors.

## CULTIVATE HEALTH SERVICES RESEARCHERS

in the blood cancer space and contribute to LLS being recognized as a funding and thought leader in this area.

# RESEARCH FUNDED

---

The Equity in Access Research Program has awarded more than \$12 million to health services researchers addressing critical issues such as the cost of oral anticancer medications, the role of health insurance in financial toxicity, and access to clinical trials.

In 2024 alone, the program awarded \$4.8 million to studies that will implement and evaluate interventions designed to improve therapeutic cancer clinical trial enrollment, particularly for underrepresented groups.



# EQUITY IN ACCESS RESEARCH PROGRAM

---

The Leukemia & Lymphoma Society's (LLS) Equity in Access Research Program was created to generate new evidence to guide policy reform and enhancements to healthcare practice and program delivery that will mitigate the impact of social, economic, and environmental disadvantages and reduce barriers to care for individuals with a blood cancer.

LLS is the largest nonprofit funder of blood cancer research, investing nearly \$1.8 billion in the most pioneering science worldwide since 1949. We drive policy and regulatory changes that accelerate the development of new blood cancer treatments and break down barriers to care.

# FUTURE OPPORTUNITIES

---

Scan here to view our funding opportunities and full list of grantees:

To connect with Equity in Access staff, email Senior Program Director, Dr. Eric Cooks at [Eric.Cooks@LLS.org](mailto:Eric.Cooks@LLS.org).



Support for this program provided by:  
**Royalty Pharma**  
**AstraZeneca**